Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has recently been highlighted as one of the 13 Best American Penny Stocks to Invest In. H.C. Wainwright reiterated its Buy rating on IOVA on February 6, setting a price target of $9 for the stock. This update came shortly after the company announced groundbreaking data regarding its commercial therapy Amtagvi (lifileucel). According to the report released by Iovance Biotherapeutics, Amtagvi demonstrated exceptional response rates in a real-world clinical study involving patients with advanced melanoma.
The data presented by IOVA showcased Amtagvi as the first one-time T cell therapy for solid tumor cancer. It is also the sole FDA-approved treatment for advanced melanoma patients who have previously undergone anti-PD-1 and targeted therapy. The results were shared during an oral session at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research.
Barclays also expressed confidence in IOVA by reiterating its Overweight rating on February 4, with a price target of $10. The company is a commercial biotechnology firm dedicated to developing tumor-infiltrating lymphocyte (TIL) therapies for cancer patients. While IOVA shows promise as an investment opportunity, there are other AI stocks that may offer higher potential returns and lower risks.
For investors seeking an undervalued AI stock with significant growth potential in light of Trump-era tariffs and the onshoring trend, Insider Monkey offers a free report on the best short-term AI stock. Additionally, readers can explore articles on 15 AI Stocks That Are Skyrocketing and 12 Best Oil and Gas Stocks to Buy Right Now for further investment insights.
Disclosure: None. This article was originally published on Insider Monkey and has been rewritten to provide a unique perspective on the developments at Iovance Biotherapeutics, Inc. (NASDAQ:IOVA).
